The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

CompanyOverview|NYSE:ABBV] If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Guggenheim on April 29, 2025. The analyst firm set a price target for $216.00 expecting ABBV to rise to within 12 months (a possible ...

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates ...

AbbVie (ABBV) closed the most recent trading ... revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. AbbVie is expected to post earnings of $3.11 ...